Profile
Business Description
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Company Info
Pennsylvania Headquarters
1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087
Telephone:
610-254-4201
Email:
info@avalotx.com
Maryland Headquarters
540 Gaither Road
Suite 400
Rockville, MD 20850
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical Preparations (2834)